Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19 (Chloroquine UN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04346329
Recruitment Status : Not yet recruiting
First Posted : April 15, 2020
Last Update Posted : April 15, 2020
Sponsor:
Collaborator:
Fundación Salud de los Andes
Information provided by (Responsible Party):
Carlos Alberto Parra Lopez, Universidad Nacional de Colombia

Brief Summary:
This is a PILOT STUDY, a Phase III double-blind, randomized, placebo-controlled clinical study in which we assess the clinical effect of the prophylactic administration of hydroxychloroquine vs. placebo to healthcare workers working at our University Hospital (HUN). Participants in each arm (n = 43) will be administered with a unique loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days. The population to be studied (uninfected healthcare personnel) will be highly exposed to SARS-CoV-2 infection. An active search should be made for individuals who become infected while participating in the study, hence, once the informed consent form is signed, the molecular test for the diagnosis of SARS-CoV-2 infection by RT-PCR will be carried out every 4 days in order to determine as closely as possible the moment the participant becomes positive. The results of the diagnostic RT-qPCR tests will be confronted with: (i) the results of immune monitoring of at least 30 immunological parameters in leukocytes and in plasma (levels of selected cytokines and chemokines analyzed by automated flow cytometry software and (ii) the daily recording of data for the presence or absence of signs and symptoms associated with SARS-Cov-2 infection. For the recording of immune monitoring 20mL blood samples will be taken at eight-time points throughout the 90 days of the stud.

Condition or disease Intervention/treatment Phase
COVID Drug: Hydroxychloroquine Drug: Placebo oral tablet Phase 3

Detailed Description:
The personnel responsible for caring of patients infected by the SARS-CoV-2 virus: doctors, nurses and paramedics working at Intensive Care Units (ICUs)), are at high risk of SARS-CoV-2 infection. Epidemiological figures suggest a high morbidity and mortality of doctors responsible for the care of infected individuals, a factor that darkens further the panorama of the current pandemic. The present proposal has two specific aims: (i) to evaluate whether hydroxychloroquine, used prophylactically at low dose (400mg/week for three months), protect against SARS-CoV-2 infection; and (ii) to examine whether exhaustion and senescence of immune system cells are associated to higher risk of SARS-CoV-2 infection. This is a PILOT STUDY, a Phase III double-blind, randomized, placebo-controlled clinical study in which we assess the clinical effect of the prophylactic administration of hydroxychloroquine vs. placebo to healthcare workers working at our University Hospital (HUN). Participants in each arm (n = 43) will be administered with a unique loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days. The population to be studied (uninfected healthcare personnel) will be highly exposed to SARS-CoV-2 infection. Taking into account that around 80% do not express symptoms or that these are mild, an active search should be made for individuals who become infected while participating in the study. For this, once the informed consent form is signed, the molecular test for the diagnosis of SARS-CoV-2 infection by RT-PCR will be carried out every 4 days in order to determine as closely as possible the moment the participant become positive. The results of the diagnostic RT-PCR tests will be confronted with: (i) the results of immune monitoring of at least 30 immunological parameters in leukocytes (number and phenotype of: PMN cells, monocytes, T- and B-lymphocytes and NK-cells) and in plasma (levels of IL-2, IL-6, IL-7, IL-10, GM-CSF, TNF-a, IP-10, MCP-1, MIP-IA, IL-1, CRP, Type IFN-alpha and IFN-betta), analyzed by automated flow cytometry software such as tSNE, SPADE, FlowSOM, among others (see attached file); and (ii) the daily recording of data on the presence or absence of signs and symptoms associated with SARS-Cov-2 infection. For the recording of immune monitoring 20mL blood samples will be taken at eight-time points (day 0) and at 8, 15, 21, 30, 45, 60 and 90 days in order to monitor the baseline of immune functionality throughout the 90 days of the study. In summary, this proposal seeks to identify immunological markers of the immune system important for defense against SARS-CoV-2, that may be useful as prognostic markers for clinical response and treatment of patients with COVID-19, and also, to evaluates whether Hydroxychloroquine, used prophylactically, has a role in protecting against SARS-CoV-2 infection in a group of healthcare workers. If hydroxychloroquine, as we all hope, turns out to be an agent that prevent SARS-Cov-2 infection, a significant group of healthcare workers at HUN at risk of becoming ill during the epidemiological peak (expected May 1st), will be protected thanks to their participation in this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase III double-blind, randomized, placebo-controlled clinical study
Masking: Double (Participant, Care Provider)
Primary Purpose: Prevention
Official Title: Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2
Estimated Study Start Date : April 20, 2020
Estimated Primary Completion Date : June 1, 2020
Estimated Study Completion Date : October 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Control
Controlled group with placebo medication similar to hydroxychloroquine (loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days)
Drug: Placebo oral tablet
Placebo Group

Experimental: treated
hydroxychloroquine with a loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days
Drug: Hydroxychloroquine
Treated group




Primary Outcome Measures :
  1. Adverse effects [ Time Frame: six months after administration of hydroxychloroquine or placebo ]
    Number of participants with treatment-related adverse events as associated administration of hydroxychloroquine or placebo.


Secondary Outcome Measures :
  1. Immune-score [ Time Frame: six months after administration of hydroxychloroquine or placebo ]
    Percentage of expression of immune senescence in cells of the immune system of individuals highly exposed to COVID-19 who receive hydroxychloroquine prophylactically vs. placebo.

  2. COVID-19 prevention [ Time Frame: six months after administration of hydroxychloroquine or placebo ]
    Correlate the immunological profile of highly exposed individuals with SARS-CoV-2 with the clinic of COVID-19.

  3. Clinical response [ Time Frame: six months after administration of hydroxychloroquine or placebo ]
    Determine the clinical outcome in observation timeframe of highly exposed personnel when receiving hydroxychloroquine vs. placebo prophylactically.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be part of the health personnel (intensivist doctor, hospital doctors, nurses, physical therapists and support staff in the care unit) who will work at the HUN in the period of May 1st, 2020 to August 1, 2020
  • Be over 18 years old, exposed to patients with COVID-19. Not having symptoms compatible with an acute respiratory infection for the last 21 days.
  • Willingness to donate blood samples and for diagnosis and monitoring of SARS-COV-2 infection throughout the study period.
  • Have a Smart Phone in order to facilitate permanent communication with you during the duration of the study.
  • Signature of informed consent.

Exclusion Criteria:

  • Allergy or hypersensitivity to hydroxychloroquine.
  • Contraindications to the use of chloroquine (epilepsy, creatinine clearance <30mL / min).
  • Be taking (Abiraterone Acetate, Agalsidase, Conivaptan, Dabrafenib, Dacomitinib, Enzalutamide, Idelalisib), or medications that cannot be discontinued.
  • Retinal disease.
  • Mifepristone, Mitotane, tiripentol.
  • Already established hydroxychloroquine treatment.
  • Pregnancy or suspected pregnancy.
  • Women in breastfeeding.
  • Chronic liver disease (Child-Pugh B or C).
  • Kidney disease with a Glomerular Filtration Rate of less than or equal to 30mL / min.
  • Cardiac, kidney, liver, ophthalmic, neurological or autoimmune disease previously diagnosed.
  • Prolongation of the QT segment in the EKG.
  • Previous diagnosis of COVID-19.
  • Concomitant taking of medications that prolong the QT segment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04346329


Locations
Layout table for location information
Colombia
Facultad de Medicina - Universidad Nacional de Colombia
Bogota, Cundinamarca, Colombia, 111321
Contact: Carlos A Parra-López, MD, PhD    +57 1 3165000 ext 15039    caparral@unal.edu.co   
Contact: David A Bernal-Estévez, MD, PhDc    +57 3105638254    dbernal.investigacion@saluddelosandes.com   
Universidad Nacional de Colombia
Bogota, Cundinamarca, Colombia, 111321
Contact: Carlos A parra-Lopez, MD PhD    3023742804    caparral@unal.edu.co   
Principal Investigator: Calos A Parra-Lopez, MD PhD         
Sub-Investigator: David A Bernal-Estevez, MD PhD         
Sponsors and Collaborators
Universidad Nacional de Colombia
Fundación Salud de los Andes
Layout table for additonal information
Responsible Party: Carlos Alberto Parra Lopez, Full Professor, Universidad Nacional de Colombia
ClinicalTrials.gov Identifier: NCT04346329    
Other Study ID Numbers: UNAL-COVID-CP
First Posted: April 15, 2020    Key Record Dates
Last Update Posted: April 15, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hydroxychloroquine
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents